Publications by authors named "Dylan Conklin"

Claim this Profile
T
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala

Breast Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.
Eric R Welin, Aurapat Ngamnithiporn, Max Klatte, Guillaume Lapointe, Gerit M Pototschnig, Dylan Conklin

Science· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Eniko Papp, Dorothy Hallberg, Gottfried E Konecny, Daniel C Bruhm, Vilmos Adleff, Dylan Conklin

Cell Rep· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition.
Maira P Campos, Melissa Cohen, Erika Von Euw, Victor Velculescu, Jennifer L Kujak, Dylan Conklin

JCO Precis Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau

Mol Cancer Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Marlena S Fejzo, Lee Anderson, Hsiao-Wang Chen, Enrique Guandique, Ondrej Kalous, Dylan Conklin

Genes Chromosomes Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
Jun Li, Wei Zhao, Rehan Akbani, Wenbin Liu, Zhenlin Ju, Dylan Conklin

Cancer Cell· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Sara A Hurvitz, Ondrej Kalous, Dylan Conklin, Amrita J Desai, Judy Dering

Breast Cancer Res Treat· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
Neil A O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
Ondrej Kalous, Dylan Conklin, Amrita J Desai, Judy Dering, Jennifer Goldstein

Breast Cancer Res Treat· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Joshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, Erika VON Euw, Dylan Conklin

Anticancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Zev A Wainberg, Adrian Anghel, Amy M Rogers, Amrita J Desai, Ondrej Kalous, Dylan Conklin

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Ondrej Kalous, Dylan Conklin, Amrita J Desai, Neil A O'Brien, Charles Ginther

Mol Cancer Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen

Breast Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis